Pharmaceutical Stocks To Follow Today – May 13th

Eli Lilly and Company, JD.com, Merck & Co., Inc., Johnson & Johnson, AbbVie, Vertex Pharmaceuticals, and Thermo Fisher Scientific are the seven Pharmaceutical stocks to watch today, according to MarketBeat’s stock screener tool. Pharmaceutical stocks are shares of publicly traded companies that research, develop, manufacture and market prescription drugs, vaccines and other therapeutic treatments. Their performance is driven by factors such as clinical?trial outcomes, regulatory approvals, patent lifecycles and healthcare policy changes, often resulting in pronounced volatility and growth potential. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.

Eli Lilly and Company (LLY)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

NYSE:LLY traded down $6.24 during mid-day trading on Tuesday, reaching $749.33. 2,760,254 shares of the stock were exchanged, compared to its average volume of 3,537,417. The business has a fifty day moving average price of $807.49 and a 200 day moving average price of $809.36. The firm has a market capitalization of $710.17 billion, a PE ratio of 63.99, a PEG ratio of 1.40 and a beta of 0.48. Eli Lilly and Company has a 1-year low of $677.09 and a 1-year high of $972.53. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00.

JD.com (JD)

JD.com, Inc. operates as a supply chain-based technology and service provider in the People's Republic of China. The company offers computers, communication, and consumer electronics products, as well as home appliances; and general merchandise products comprising food, beverage and fresh produce, baby and maternity products, furniture and household goods, cosmetics and other personal care items, pharmaceutical and healthcare products, industrial products, books, automobile accessories, apparel and footwear, bags, and jewelry.

Shares of NASDAQ:JD traded up $1.57 during midday trading on Tuesday, reaching $37.62. The company had a trading volume of 33,063,025 shares, compared to its average volume of 14,366,783. The company has a debt-to-equity ratio of 0.18, a quick ratio of 0.90 and a current ratio of 1.17. JD.com has a 1-year low of $24.13 and a 1-year high of $47.82. The firm has a market cap of $59.33 billion, a price-to-earnings ratio of 11.91, a price-to-earnings-growth ratio of 0.31 and a beta of 0.56. The company has a fifty day simple moving average of $37.69 and a two-hundred day simple moving average of $37.95.

Merck & Co., Inc. (MRK)

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

Shares of Merck & Co., Inc. stock traded down $2.69 on Tuesday, hitting $77.74. 13,811,291 shares of the company traded hands, compared to its average volume of 12,232,234. The company has a market cap of $195.21 billion, a PE ratio of 11.55, a PEG ratio of 0.77 and a beta of 0.43. The company has a 50-day moving average price of $85.01 and a 200 day moving average price of $92.97. Merck & Co., Inc. has a 12-month low of $75.82 and a 12-month high of $134.63. The company has a quick ratio of 1.15, a current ratio of 1.36 and a debt-to-equity ratio of 0.79.

Johnson & Johnson (JNJ)

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Johnson & Johnson stock traded down $4.64 during trading hours on Tuesday, reaching $149.50. 6,065,062 shares of the company were exchanged, compared to its average volume of 7,897,976. The firm has a market cap of $359.71 billion, a price-to-earnings ratio of 22.48, a PEG ratio of 2.56 and a beta of 0.42. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. The stock has a 50-day moving average of $157.67 and a 200 day moving average of $154.18. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99.

AbbVie (ABBV)

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

Shares of NYSE ABBV traded down $0.47 during trading hours on Tuesday, reaching $189.60. The stock had a trading volume of 4,607,425 shares, compared to its average volume of 6,154,386. The business’s fifty day moving average is $193.79 and its two-hundred day moving average is $187.23. The company has a debt-to-equity ratio of 17.94, a current ratio of 0.66 and a quick ratio of 0.55. The company has a market cap of $335.40 billion, a price-to-earnings ratio of 79.00, a PEG ratio of 1.62 and a beta of 0.56. AbbVie has a twelve month low of $153.58 and a twelve month high of $218.66.

Vertex Pharmaceuticals (VRTX)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

Shares of NASDAQ VRTX traded up $0.90 during midday trading on Tuesday, reaching $440.27. 1,679,445 shares of the company traded hands, compared to its average volume of 1,395,437. The firm has a market cap of $113.06 billion, a PE ratio of -200.12, a PEG ratio of 2.11 and a beta of 0.51. The stock’s 50-day simple moving average is $487.70 and its 200-day simple moving average is $465.56. Vertex Pharmaceuticals has a 12 month low of $377.85 and a 12 month high of $519.88. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.35 and a current ratio of 2.69.

Thermo Fisher Scientific (TMO)

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Shares of NYSE:TMO traded down $1.74 during midday trading on Tuesday, reaching $430.85. The company’s stock had a trading volume of 1,684,451 shares, compared to its average volume of 1,806,910. The business’s fifty day simple moving average is $462.82 and its 200-day simple moving average is $513.70. The company has a market capitalization of $162.64 billion, a P/E ratio of 26.06, a P/E/G ratio of 2.99 and a beta of 0.82. Thermo Fisher Scientific has a fifty-two week low of $401.75 and a fifty-two week high of $627.88. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29.